In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Naproxen Cardio Benefit “Not Large Enough” To Back Vioxx Defense – Lancet

This article was originally published in The Tan Sheet

Executive Summary

Naproxen's perceived cardioprotective benefit demonstrated in studies likely is due to coincidence, according to a recent study published in the Lancet

You may also be interested in...



FDA’s Graham Casts Doubt On Naproxen Cardioprotection, Vioxx Defense

Debate during a three-day panel meeting on the safety of COX-2s and NSAIDs appeared to reach a consensus that naproxen carries little to no cardioprotective benefit

FDA’s Graham Casts Doubt On Naproxen Cardioprotection, Vioxx Defense

Debate during a three-day panel meeting on the safety of COX-2s and NSAIDs appeared to reach a consensus that naproxen carries little to no cardioprotective benefit

FDA’s Graham Casts Doubt On Naproxen Cardioprotection, Vioxx Defense

Debate during a three-day panel meeting on the safety of COX-2s and NSAIDs appeared to reach a consensus that naproxen carries little to no cardioprotective benefit

Related Content

Topics

UsernamePublicRestriction

Register

PS097522

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel